Ipsen Biopharmaceuticals, Inc. et al. v. Conjupro Biotherapeutics, Inc. et al.
consolidated; administratively terminated- Docket:
- 1:24-cv-08723
- Filed:
- 2024-08-23
- Terminated:
- 2024-10-18
Patents:12059497
π Ipsen Biopharmaceuticals, Inc.π Ipsen Biopharm Ltd.Δ Conjupro Biotherapeutics, Inc.Δ CSPC Pharmaceutical Group LimitedΔ CSPC Ouyi Pharmaceutical Co., Ltd.
Ipsen asserted U.S. Patent No. 12,059,497 under 35 U.S.C. § 271(e)(2)(A) against Conjupro/CSPC based on NDA No. 218923 for irinotecan liposome injection. The case was consolidated into 1:24-cv-04991 on October 18, 2024 for all purposes and administratively terminated; the consolidated action remains pending in discovery.